Jennifer Chan, MD, MPH, clinical director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute, discusses a study exploring cabozantinib (Cabometyx) for the treatment of patients with advanced carcinoid and pancreatic neuroendocrine tumors.
Study Reveals Encouraging Results in HER2+ Breast Cancer With Brain Mets
November 1st 2024Barbara O’Brien, MD, discussed findings and implications from the phase 2 TBCRC049 study evaluating the combination of tucatinib, trastuzumab, and capecitabine in HER2-positive breast cancer with leptomeningeal metastasis.
Read More